From Cancer Communicator
News & Analysis
Conference coverage, FDA updates, clinical trial analysis, and more.
-
FDA Approves Epcoritamab with Rituximab and Lenalidomide for R/R FL
On November 18, 2025, the US Food and Drug Administration approved epcoritamab-bysp in combination with rituximab and lenalidomide for adult patients with relapsed or…
-
New Interchangeable Pertuzumab Biosimilar Approved for HER2-Positive Breast Cancer
On November 13, 2025, the US Food and Drug Administration approved pertuzumab-dpzb (Poherdy) as an interchangeable biosimilar to pertuzumab (Perjeta) for the treatment of…
-
Ziftomenib Approved for NPM1-Mutant R/R AML
On November 13, 2025, the US Food and Drug Administration approved the menin inhibitor ziftomenib (Komzifti) for adult patients with relapsed or refractory acute…
-
ESMO25: Neoadjuvant T-DXd Combo Tops Anthracycline Standard With Less Toxicity in HER2+ eBC
At the 2025 European Society for Medical Oncology (ESMO) Congress, Nadia Harbeck, MD, of the University of Munich, presented results of the phase 3…
-
Four-Year Median OS with Osimertinib/ Chemotherapy Combination in Advanced EGFR-Mutation Positive NSCLC
he final overall survival (OS) analysis from the FLAURA2 trial was presented during the International Association for the Study of Lung Cancer (IASLC) 2025…
-
FDA Approves Sunvozertinib for EGFR Exon 20 Insertion-Positive Metastatic NSCLC
On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib for patients with locally advanced or metastatic non-small…